Evidence map›Paper›PMID 38192747›Full record

ArticleThe Lancet regional health. Western Pacific2024

Estimating the population-level impacts of improved uptake of SGLT2 inhibitors in patients with chronic kidney disease: a cross-sectional observational study using routinely collected Australian primary care data.

Brendon L Neuen, Min Jun, James Wick, Sradha Kotwal, Sunil V Badve, Meg J Jardine, Martin Gallagher, John Chalmers, Kellie Nallaiah, Vlado Perkovic and 4 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The Lancet regional health. Western Pacific, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
4.8field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 24 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 6 institutions in 3 countries.

Brendon L NeuenFaculty of Medicine and Health, The George Institute for Global Health, University of New South Wales, Sydney, Australia.
Min JunFaculty of Medicine and Health, The George Institute for Global Health, University of New South Wales, Sydney, Australia.
James WickDepartment of Medicine, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.
Sradha KotwalFaculty of Medicine and Health, The George Institute for Global Health, University of New South Wales, Sydney, Australia.
Sunil V BadveFaculty of Medicine and Health, The George Institute for Global Health, University of New South Wales, Sydney, Australia.
Meg J JardineNHMRC Clinical Trials Centre, University of Sydney, New South Wales, Australia.
Martin GallagherFaculty of Medicine and Health, The George Institute for Global Health, University of New South Wales, Sydney, Australia.
John ChalmersFaculty of Medicine and Health, The George Institute for Global Health, University of New South Wales, Sydney, Australia.
Kellie NallaiahFaculty of Medicine and Health, The George Institute for Global Health, University of New South Wales, Sydney, Australia.
Vlado PerkovicFaculty of Medicine and Health, The George Institute for Global Health, University of New South Wales, Sydney, Australia.
David PeirisFaculty of Medicine and Health, The George Institute for Global Health, University of New South Wales, Sydney, Australia.
Anthony RodgersFaculty of Medicine and Health, The George Institute for Global Health, University of New South Wales, Sydney, Australia.
Mark WoodwardFaculty of Medicine and Health, The George Institute for Global Health, University of New South Wales, Sydney, Australia.
Paul E RonksleyDepartment of Community Health Sciences, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.
UNSW Sydney · AUUniversity of Calgary · CALiverpool Hospital · AURoyal North Shore Hospital · AUThe George Institute for Global Health · GBThe University of Sydney · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Sodium glucose co-transporter 2 (SGLT2) inhibitors reduce the risk of kidney failure and death in patients with chronic kidney disease (CKD) but are underused. We evaluated the number of patients with CKD in Australia that would be eligible for treatment and estimated the number of cardiorenal and kidney failure events that could be averted with improved uptake of SGLT2 inhibitors. Methods: This cross-sectional observational study leveraged nationally representative primary care data from 392 Australian general practices (MedicineInsight) between 1 January 2020 and 31 December 2021. We identified patients that would have met inclusion criteria of key SGLT2 inhibitor trials and applied these data to age and sex-stratified estimates of CKD prevalence for the Australian population (using national census data), estimating the number of preventable events using trial event rates. Key outcomes included cardiorenal events (CKD progression, kidney failure, or death due to cardiovascular or kidney disease) and kidney failure. Findings: In MedicineInsight, 44.2% of adults with CKD would have met CKD eligibility criteria for an SGLT2 inhibitor; baseline use was 4.1%. Applying these data to the Australian population, 230,246 patients with CKD would have been eligible for treatment with an SGLT2 inhibitor. Optimal implementation of SGLT2 inhibitors (75% uptake) could reduce cardiorenal and kidney failure events annually in Australia by 3644 (95% CI 3526-3764) and 1312 (95% CI 1242-1385), respectively. Interpretation: Improved uptake of SGLT2 inhibitors for patients with CKD in Australia has the potential to prevent large numbers of patients experiencing CKD progression or dying due to cardiovascular or kidney disease. Identifying strategies to increase the uptake of SGLT2 inhibitors is critical to realising the population-level benefits of this drug class. Funding: University of New South Wales Scientia Program and Boehringer IngelheimEli Lilly Alliance.

Indexed as

Cardiovascular diseaseChronic kidney diseaseEnd-stage kidney diseaseEpidemiologySodium glucose cotransporter 2 inhibitors

Identifiers

PMID38192747
PMCPMC10772282
OpenAlexW4389899331

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.